Celiac Disease Foundation Debuts Innovative iRecruitCeliac Patient Recruitment Platform
The Celiac Disease Foundation, a trusted partner in optimizing patient recruitment and retention, today announces the launch of its iRecruitCeliac platform, which brings together solutions to accelerate enrollment in clinical trials for celiac disease and comorbid conditions. With an established, 30-year track…
ReAlta Life Sciences annuncia una presentazione importante al European Respiratory Society 2023 International Congress
ReAlta Life Sciences, Inc. è un’azienda di biotech clinical-stage impegnata nell’usare la potenza del sistema immunitario per contrastare e risolvere situazioni come malattie rare e malattie infiammatorie acute potenzialmente letali. L’azienda ha oggi annunciato che presenterà ulteriori dati clinica dal…
CVS Health expands access to life-saving medication naloxone by offering over-the-counter NARCAN
Following FDA approval, CVS Pharmacy® is now offering over-the-counter (OTC) naloxone, brand name NARCAN®, at more than 7,500 locations nationwide, making it easier and more discrete than ever to purchase the safe and effective antidote to opioid overdoses. What is naloxone? Available…
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization for the companies’ Omicron XBB.1.5-adapted monovalent COVID-19 vaccine (COMIRNATY® Omicron XBB.1.5) administered as…
Pfizer Invites Public to View and Listen to Two Webcasts of Pfizer Discussions at Healthcare Conferences
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to two upcoming webcasts of Pfizer discussions at healthcare conferences: To view and listen to the webcasts, visit our web site at www.pfizer.com Information on accessing and…
Cardinal Health Launches Next Generation Medical Device to Improve Neonatal Feeding
Cardinal Health (NYSE: CAH) announced today the launch of its next generation NTrainer™ System 2.0, a medical device designed to help premature and newborn infants develop the oral coordination skills important for the transition to independent feeding faster, thus helping…
Global Urinary Incontinence Markets, 2018-2022 & 2023-2028: Companies Innovate Advertisements to Promote Urinary Incontinence Awareness as Disposables Dominate – ResearchAndMarkets.com
The “Global Urinary Incontinence Market (2023 Edition) – Analysis By Incontinence Type (Stress, Urge, Mixed, Others), Product Type, End-user, By Region, By Country: Market Size, Insights, Competition, Covid-19 Impact and Forecast (2023-2028)” report has been added to ResearchAndMarkets.com’s offering. The Global Urinary Incontinence Market…
Dexcom G6 Strengthens Its Position as World’s Most Connected CGM System With a New Aid Offering in Germany
DexCom, Inc. (Nasdaq: DXCM), global manufacturer of systems for real-time continuous glucose monitoring for people with diabetes, today announced the Dexcom G6 Real-Time Continuous Glucose Monitoring System (rt-CGM) is the first and only CGM to connect to the Omnipod 5 AID…
Aditxt Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has entered into definitive agreements for the purchase and sale of…
Rapid Medical™ Licenses World’s Only Adjustable Thrombectomy Device in China
Rapid Medical™, a leading developer of advanced neurovascular devices, announced Chinese approval of its TIGERTRIEVER revascularization device. With this milestone approval from the National Medical Products Administration (NMPA), TIGERTRIEVER becomes the first device to offer patient-specific solutions to remove blood clots from the brain…
Elastin Biosciences Announces Breakthrough Discovery in Elastin Restoration: Paving the Way for Treatment of Elastin-Deficiency Diseases
Longaevus Technologies, announces the spin-off of Elastin Biosciences following breakthrough preclinical results of 3 of its assets. Longaevus Technologies is a company builder with dedicated to longevity, with an all-round approach to reversing aging based on its multiple hallmarks. Longaevus…
Novartis presents new long-term Leqvio® (inclisiran) data demonstrating consistent efficacy and safety beyond six years
Novartis today announced new long-term data from ORION-8, a Phase III open-label extension of ORION-9, ORION-10, ORION-11 and ORION-3 trials. The data demonstrated that with twice-yearly* dosing, Leqvio, in addition to statin therapy, provides consistent low-density lipoprotein cholesterol (LDL-C) reduction…